M J Overman1, V Morris2, B Kee2, D Fogelman2, L Xiao3, C Eng2, A Dasari2, R Shroff2, T Mazard2, K Shaw4, E Vilar5, K Raghav2, I Shureiqi2, L Liang3, G B Mills6, R A Wolff2, S Hamilton7, F Meric-Bernstam8, J Abbruzzese9, J Morris3, D Maru7, S Kopetz2. 1. Department of Gastrointestinal Medical Oncology. Electronic address: moverman@mdanderson.org. 2. Department of Gastrointestinal Medical Oncology. 3. Department of Biostatistics. 4. Department of Sheikh Khalifa Nahyan Ben Zayed Institute for Personalized Cancer Therapy. 5. Department of Gastrointestinal Medical Oncology; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston. 6. Department of Sheikh Khalifa Nahyan Ben Zayed Institute for Personalized Cancer Therapy; Department of Systems Biology. 7. Department of Pathology. 8. Department of Sheikh Khalifa Nahyan Ben Zayed Institute for Personalized Cancer Therapy; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA. 9. Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham.
Abstract
BACKGROUND: Incorporation of multiple enrichment biomarkers into prospective clinical trials is an active area of investigation, but the factors that determine clinical trial enrollment following a molecular prescreening program have not been assessed. PATIENTS AND METHODS: Patients with 5-fluorouracil-refractory metastatic colorectal cancer at the MD Anderson Cancer Center were offered screening in the Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC) program to identify eligibility for companion phase I or II clinical trials with a therapy targeted to an aberration detected in the patient, based on testing by immunohistochemistry, targeted gene sequencing panels, and CpG island methylation phenotype assays. RESULTS: Between August 2010 and December 2013, 484 patients were enrolled, 458 (95%) had a biomarker result, and 157 (32%) were enrolled on a clinical trial (92 on biomarker-selected and 65 on nonbiomarker selected). Of the 458 patients with a biomarker result, enrollment on biomarker-selected clinical trials was ninefold higher for predefined ATTACC-companion clinical trials as opposed to nonpredefined biomarker-selected clinical trials, 17.9% versus 2%, P < 0.001. Factors that correlated positively with trial enrollment in multivariate analysis were higher performance status, older age, lack of standard of care therapy, established patient at MD Anderson, and the presence of an eligible biomarker for an ATTACC-companion study. Early molecular screening did result in a higher rate of patients with remaining standard of care therapy enrolling on ATTACC-companion clinical trials, 45.1%, in contrast to nonpredefined clinical trials, 22.7%; odds ratio 3.1, P = 0.002. CONCLUSIONS: Though early molecular prescreening for predefined clinical trials resulted in an increase rate of trial enrollment of nonrefractory patients, the majority of patients enrolled on clinical trials were refractory to standard of care therapy. Within molecular prescreening programs, tailoring screening for preidentified and open clinical trials, temporally linking screening to treatment and optimizing both patient and physician engagement are efforts likely to improve enrollment on biomarker-selected clinical trials. CLINICAL TRIALS NUMBER: The study NCT number is NCT01196130.
BACKGROUND: Incorporation of multiple enrichment biomarkers into prospective clinical trials is an active area of investigation, but the factors that determine clinical trial enrollment following a molecular prescreening program have not been assessed. PATIENTS AND METHODS: Patients with 5-fluorouracil-refractory metastatic colorectal cancer at the MD Anderson Cancer Center were offered screening in the Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC) program to identify eligibility for companion phase I or II clinical trials with a therapy targeted to an aberration detected in the patient, based on testing by immunohistochemistry, targeted gene sequencing panels, and CpG island methylation phenotype assays. RESULTS: Between August 2010 and December 2013, 484 patients were enrolled, 458 (95%) had a biomarker result, and 157 (32%) were enrolled on a clinical trial (92 on biomarker-selected and 65 on nonbiomarker selected). Of the 458 patients with a biomarker result, enrollment on biomarker-selected clinical trials was ninefold higher for predefined ATTACC-companion clinical trials as opposed to nonpredefined biomarker-selected clinical trials, 17.9% versus 2%, P < 0.001. Factors that correlated positively with trial enrollment in multivariate analysis were higher performance status, older age, lack of standard of care therapy, established patient at MD Anderson, and the presence of an eligible biomarker for an ATTACC-companion study. Early molecular screening did result in a higher rate of patients with remaining standard of care therapy enrolling on ATTACC-companion clinical trials, 45.1%, in contrast to nonpredefined clinical trials, 22.7%; odds ratio 3.1, P = 0.002. CONCLUSIONS: Though early molecular prescreening for predefined clinical trials resulted in an increase rate of trial enrollment of nonrefractory patients, the majority of patients enrolled on clinical trials were refractory to standard of care therapy. Within molecular prescreening programs, tailoring screening for preidentified and open clinical trials, temporally linking screening to treatment and optimizing both patient and physician engagement are efforts likely to improve enrollment on biomarker-selected clinical trials. CLINICAL TRIALS NUMBER: The study NCT number is NCT01196130.
Authors: Ariel Lopez-Chavez; Anish Thomas; Arun Rajan; Mark Raffeld; Betsy Morrow; Ronan Kelly; Corey Allan Carter; Udayan Guha; Keith Killian; Christopher C Lau; Zied Abdullaev; Liqiang Xi; Svetlana Pack; Paul S Meltzer; Christopher L Corless; Alan Sandler; Carol Beadling; Andrea Warrick; David J Liewehr; Seth M Steinberg; Arlene Berman; Austin Doyle; Eva Szabo; Yisong Wang; Giuseppe Giaccone Journal: J Clin Oncol Date: 2015-02-09 Impact factor: 44.544
Authors: Mark G Kris; Bruce E Johnson; Lynne D Berry; David J Kwiatkowski; A John Iafrate; Ignacio I Wistuba; Marileila Varella-Garcia; Wilbur A Franklin; Samuel L Aronson; Pei-Fang Su; Yu Shyr; D Ross Camidge; Lecia V Sequist; Bonnie S Glisson; Fadlo R Khuri; Edward B Garon; William Pao; Charles Rudin; Joan Schiller; Eric B Haura; Mark Socinski; Keisuke Shirai; Heidi Chen; Giuseppe Giaccone; Marc Ladanyi; Kelly Kugler; John D Minna; Paul A Bunn Journal: JAMA Date: 2014-05-21 Impact factor: 56.272
Authors: Lorraine A Chantrill; Adnan M Nagrial; Clare Watson; Amber L Johns; Mona Martyn-Smith; Skye Simpson; Scott Mead; Marc D Jones; Jaswinder S Samra; Anthony J Gill; Nicole Watson; Venessa T Chin; Jeremy L Humphris; Angela Chou; Belinda Brown; Adrienne Morey; Marina Pajic; Sean M Grimmond; David K Chang; David Thomas; Lucille Sebastian; Katrin Sjoquist; Sonia Yip; Nick Pavlakis; Ray Asghari; Sandra Harvey; Peter Grimison; John Simes; Andrew V Biankin Journal: Clin Cancer Res Date: 2015-05-01 Impact factor: 12.531
Authors: P N Lara; R Higdon; N Lim; K Kwan; M Tanaka; D H Lau; T Wun; J Welborn; F J Meyers; S Christensen; R O'Donnell; C Richman; S A Scudder; J Tuscano; D R Gandara; K S Lam Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Ronald S Go; Kathleen A Frisby; Jennifer A Lee; Michelle A Mathiason; Christine M Meyer; Jodi L Ostern; Sara M Walther; Jonean E Schroeder; Lori A Meyer; Kathryn E Umberger Journal: Cancer Date: 2006-01-15 Impact factor: 6.860
Authors: Funda Meric-Bernstam; Lauren Brusco; Kenna Shaw; Chacha Horombe; Scott Kopetz; Michael A Davies; Mark Routbort; Sarina A Piha-Paul; Filip Janku; Naoto Ueno; David Hong; John De Groot; Vinod Ravi; Yisheng Li; Raja Luthra; Keyur Patel; Russell Broaddus; John Mendelsohn; Gordon B Mills Journal: J Clin Oncol Date: 2015-05-26 Impact factor: 44.544
Authors: Celia P Kaplan; Anna Maria Nápoles; Daniel Dohan; E Shelley Hwang; Michelle Melisko; Dana Nickleach; Jessica Ann Quinn; Jennifer Haas Journal: Cancer Causes Control Date: 2013-02-19 Impact factor: 2.506
Authors: Seung Tae Kim; Kyoung-Mee Kim; Nayoung K D Kim; Joon Oh Park; Soomin Ahn; Jae-Won Yun; Kyu-Tae Kim; Se Hoon Park; Peter J Park; Hee Cheol Kim; Tae Sung Sohn; Dong Il Choi; Jong Ho Cho; Jin Seok Heo; Wooil Kwon; Hyuk Lee; Byung-Hoon Min; Sung No Hong; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Woong-Yang Park; Jeeyun Lee Journal: Oncologist Date: 2017-07-12
Authors: Yun Shin Chun; Guillaume Passot; Suguru Yamashita; Maliha Nusrat; Panagiotis Katsonis; Jonathan M Loree; Claudius Conrad; Ching-Wei D Tzeng; Lianchun Xiao; Thomas A Aloia; Cathy Eng; Scott E Kopetz; Olivier Lichtarge; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2019-05 Impact factor: 12.969
Authors: Daniel H Hovelson; Chia-Jen Liu; Yugang Wang; Qing Kang; James Henderson; Amy Gursky; Scott Brockman; Nithya Ramnath; John C Krauss; Moshe Talpaz; Malathi Kandarpa; Rashmi Chugh; Missy Tuck; Kirk Herman; Catherine S Grasso; Michael J Quist; Felix Y Feng; Christine Haakenson; John Langmore; Emmanuel Kamberov; Tim Tesmer; Hatim Husain; Robert J Lonigro; Dan Robinson; David C Smith; Ajjai S Alva; Maha H Hussain; Arul M Chinnaiyan; Muneesh Tewari; Ryan E Mills; Todd M Morgan; Scott A Tomlins Journal: Oncotarget Date: 2017-09-22
Authors: Allan A Lima Pereira; Maria Pia Morelli; Michael Overman; Bryan Kee; David Fogelman; Eduardo Vilar; Imad Shureiqi; Kanwal Raghav; Cathy Eng; Shanequa Manuel; Shadarra Crosby; Robert A Wolff; Kimberly Banks; Richard Lanman; AmirAli Talasaz; Scott Kopetz; Van Morris Journal: PLoS One Date: 2017-08-29 Impact factor: 3.240
Authors: Scott Kopetz; Dipen M Maru; Jeffrey S Morris; Rajyalakshmi Luthra; Yusha Liu; Dzifa Y Duose; Wonyul Lee; Neelima G Reddy; Justin Windham; Huiqin Chen; Zhimin Tong; Baili Zhang; Wei Wei; Manyam Ganiraju; Bradley M Broom; Hector A Alvarez; Alicia Mejia; Omkara Veeranki; Mark J Routbort; Van K Morris; Michael J Overman; David Menter; Riham Katkhuda; Ignacio I Wistuba; Jennifer S Davis Journal: Clin Cancer Res Date: 2020-10-27 Impact factor: 13.801